^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    puqilunsai (pCAR-19B)

    i
    Other names: pCAR-19B, CD19-targeted CAR-T therapy, CD19 CAR-T cells, pCAR-19B cells, MC-1-50
    Company:
    Chongqing Precision Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    2ms
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    puqilunsai (pCAR-19B)
    4ms
    Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis (clinicaltrials.gov)
    P1, N=10, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    puqilunsai (pCAR-19B)
    5ms
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (clinicaltrials.gov)
    P2, N=100, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    11ms
    Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=19, Recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial • CAR T-Cell Therapy
    |
    puqilunsai (pCAR-19B)
    1year
    a Phase I Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 positive
    |
    puqilunsai (pCAR-19B)
    1year
    Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=54, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    over1year
    Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    puqilunsai (pCAR-19B)
    over1year
    CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    puqilunsai (pCAR-19B)
    over2years
    Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=54, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    over2years
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (clinicaltrials.gov)
    P2, N=100, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P2 trial
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6)
    |
    CD19 expression
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    almost3years
    Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (clinicaltrials.gov)
    P1, N=9, Completed, Chongqing Precision Biotech Co., Ltd | Recruiting --> Completed | N=18 --> 9
    Trial completion • Enrollment change
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6)
    |
    CD19 expression
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    over3years
    Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6)
    |
    CD19 expression
    |
    puqilunsai (pCAR-19B)
    over3years
    Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6)
    |
    CD19 expression
    |
    puqilunsai (pCAR-19B)